Clinical Trial Update: A Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' RSV Investigational Vaccine (ChAd155-RSV) (GSK3389245A) in Healthy Adults [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety and immunogenicity of GSK's RSV vaccine ChAd155-RSV (GSK3389245A) in healthy adults completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infections

Drugs mentioned

• ChAd155-RSV (GSK3389245A)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Respiratory Synctial Virus Infections | Phase 1 | Status: COMPLETED | Results posted: 2018-08-20